Zhi-Bin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhi-Bin Wang has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Shi-Long Jiang
Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China
2 shared publicationsZe-Wu Zhu
Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China
2 shared publicationsChan Zou
Center for Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, PR China
1 shared publicationChao Luo
Shanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai 200030, PR China
1 shared publication- Chen-Xue Mao
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha 410008, China
1 shared publication De-Hua Liao
Department of Pharmacy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/ Hunan Cancer Hospital, Changsha, Hunan, 410013, PR China
1 shared publication
Latest Publications
- Open Access
- 29 January 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16
Spatial profiling of the metabolism-immune axis in ovarian cancer
Ovarian cancer remains a lethal disease marked by profound therapeutic resistance, largely orchestrated by a complex tumor microenvironment (TME) governed by metabolism-immune crosstalk. This review focuses on the spatiotemporal dynamics of the metabolism-immune axis in ovarian cancer progression and resistance, with particular emphasis on how cutting-edge spatial multi-omics technologies reveal previously unrecognized layers of intratumoral heterogeneity and geographic organization that cannot be captured by bulk analyses. Using tools such as MALDI-MSI, GeoMx DSP, and CODEX, these approaches enable high-resolution, spatially resolved mapping of metabolite gradients (e.g., lactate, lipids, kynurenine), immune cell niches, and immunometabolic checkpoints within distinct tumor regions. Such spatial profiling uncovers how metabolic reprogramming-dysregulated glycolysis, lipid metabolism, and glutaminolysis-drives localized immunosuppression and chemoresistance through compartment-specific interactions among tumor cells, cancer-associated fibroblasts (CAFs), adipocytes, and immune populations. These geographically defined insights reshape our understanding of therapeutic failure and highlight precise, location-aware vulnerabilities. Accordingly, we propose spatially informed therapeutic strategies, including regional glycolysis inhibition, glutaminase blockade, lipid pathway interference, and their rational combination with immune checkpoint inhibitors (ICIs), to disrupt pathogenic metabolic-immune circuits and improve immunotherapy outcomes. Looking ahead, advances in vivo spatial imaging, gut microbiota modulation, and AI-powered integrative multi-omics frameworks promise truly personalized treatment of ovarian cancer.
- 29 January 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16
Open AccessSpatial profiling of the metabolism-immune axis in ovarian cancer
Ovarian cancer remains a lethal disease marked by profound therapeutic resistance, largely orchestrated by a complex tumor microenvironment (TME) governed by metabolism-immune crosstalk. This review focuses on the spatiotemporal dynamics of the metabolism-immune axis in ovarian cancer progression and resistance, with particular emphasis on how cutting-edge spatial multi-omics technologies reveal previously unrecognized layers of intratumoral heterogeneity and geographic organization that cannot be captured by bulk analyses. Using tools such as MALDI-MSI, GeoMx DSP, and CODEX, these approaches enable high-resolution, spatially resolved mapping of metabolite gradients (e.g., lactate, lipids, kynurenine), immune cell niches, and immunometabolic checkpoints within distinct tumor regions. Such spatial profiling uncovers how metabolic reprogramming-dysregulated glycolysis, lipid metabolism, and glutaminolysis-drives localized immunosuppression and chemoresistance through compartment-specific interactions among tumor cells, cancer-associated fibroblasts (CAFs), adipocytes, and immune populations. These geographically defined insights reshape our understanding of therapeutic failure and highlight precise, location-aware vulnerabilities. Accordingly, we propose spatially informed therapeutic strategies, including regional glycolysis inhibition, glutaminase blockade, lipid pathway interference, and their rational combination with immune checkpoint inhibitors (ICIs), to disrupt pathogenic metabolic-immune circuits and improve immunotherapy outcomes. Looking ahead, advances in vivo spatial imaging, gut microbiota modulation, and AI-powered integrative multi-omics frameworks promise truly personalized treatment of ovarian cancer.
- 29 December 2025
- Published by Elsevier in Metabolism
- Vol. 176, 156486
TRP channels at the crossroads of metabolism and immunity: ion–metabolite coupling in inflammation and disease
- 29 December 2025
- Published by Elsevier in Metabolism
- Vol. 176, 156486
TRP channels at the crossroads of metabolism and immunity: ion–metabolite coupling in inflammation and disease
- 8 August 2025
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 274, 108906
Macrophages at the crossroads of cellular senescence and cancer development and progression: Therapeutic opportunities and challenges
- 8 August 2025
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 274, 108906
Macrophages at the crossroads of cellular senescence and cancer development and progression: Therapeutic opportunities and challenges
- Open Access
- 19 June 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1229785
Editorial: Targeting oxidative stress in cancer: what is new in the prevention, diagnostic, treatment and prognostic strategies?
Editorial: Targeting oxidative stress in cancer: what is new in the prevention, diagnostic, treatment and prognostic strategies?
- 19 June 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1229785
Open AccessEditorial: Targeting oxidative stress in cancer: what is new in the prevention, diagnostic, treatment and prognostic strategies?
Editorial: Targeting oxidative stress in cancer: what is new in the prevention, diagnostic, treatment and prognostic strategies?
- Open Access
- 28 October 2016
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (11) , 1808
PPIC, EMP3 and CHI3L1 Are Novel Prognostic Markers for High Grade Glioma
Current treatment methods for patients diagnosed with gliomas have shown limited success. This is partly due to the lack of prognostic genes available to accurately predict disease outcomes. The aim of this study was to investigate novel prognostic genes based on the molecular profile of tumor samples and their correlation with clinical parameters. In the current study, microarray data (GSE4412 and GSE7696) downloaded from Gene Expression Omnibus were used to identify differentially expressed prognostic genes (DEPGs) by significant analysis of microarray (SAM) between long-term survivors (>2 years) and short-term survivors (≤2 years). DEPGs generated from these two datasets were intersected to obtain a list of common DEPGs. The expression of a subset of common DEPGs was then independently validated by real-time reverse transcription quantitative PCR (qPCR). Survival value of the common DEPGs was validated using known survival data from the GSE4412 and TCGA dataset. After intersecting DEPGs generated from the above two datasets, three genes were identified which may potentially be used to determine glioma patient prognosis. Independent validation with glioma patients tissue (n = 70) and normal brain tissue (n = 19) found PPIC, EMP3 and CHI3L1 were up-regulated in glioma tissue. Survival value validation showed that the three genes correlated with patient survival by Kaplan-Meir analysis, including grades, age and therapy.
- 28 October 2016
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (11) , 1808
Open AccessPPIC, EMP3 and CHI3L1 Are Novel Prognostic Markers for High Grade Glioma
Current treatment methods for patients diagnosed with gliomas have shown limited success. This is partly due to the lack of prognostic genes available to accurately predict disease outcomes. The aim of this study was to investigate novel prognostic genes based on the molecular profile of tumor samples and their correlation with clinical parameters. In the current study, microarray data (GSE4412 and GSE7696) downloaded from Gene Expression Omnibus were used to identify differentially expressed prognostic genes (DEPGs) by significant analysis of microarray (SAM) between long-term survivors (>2 years) and short-term survivors (≤2 years). DEPGs generated from these two datasets were intersected to obtain a list of common DEPGs. The expression of a subset of common DEPGs was then independently validated by real-time reverse transcription quantitative PCR (qPCR). Survival value of the common DEPGs was validated using known survival data from the GSE4412 and TCGA dataset. After intersecting DEPGs generated from the above two datasets, three genes were identified which may potentially be used to determine glioma patient prognosis. Independent validation with glioma patients tissue (n = 70) and normal brain tissue (n = 19) found PPIC, EMP3 and CHI3L1 were up-regulated in glioma tissue. Survival value validation showed that the three genes correlated with patient survival by Kaplan-Meir analysis, including grades, age and therapy.